Drug intelligence / Profile preview

CXG90

Development stage: Preclinical
Lead developer: Chance Pharmaceuticals
Modality: Small Molecules

Overview

CXG90 is a small molecule drug under preclinical development by Hangzhou Chance Pharmaceuticals. It acts as a multi-target agent with three distinct mechanisms of action: - Glucocorticoid receptor (GR) modulator - Muscarinic acetylcholine receptor (mAChR) antagonist - Beta-2 adrenergic receptor (β2-adrenergic receptor) agonist The drug is being developed primarily for immune system and respiratory diseases, with active indications including asthma and chronic obstructive pulmonary disease (COPD). Its multi-modal mechanism suggests potential for both anti-inflammatory effects and bronchodilation[1].

Targets

GR (Glucocorticoid receptor)mAChR (Muscarinic acetylcholine receptors)ADRB2 (β2)

Beyond the preview

Go deeper on CXG90.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CXG90.

Explore the full profile